Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636 1637 1653 1682
This examiner grants 53% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17273065 | High-Throughput Screening Platform for Longevity Genes and Anti-Aging Drugs | Final Rejection | The Regents of the University of California |
| 18469344 | SERPINA-MODULATING COMPOSITIONS AND METHODS | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 19223597 | CHEMICALLY MODIFIED ANTISENSE OLIGONUCLEOTIDES (ASOS) AND COMPOSITIONS COMPRISING THE SAME FOR RNA EDITING | Final Rejection | Eberhard Karls Universität Tübingen |
| 17831232 | INTEGRATED DRUG DISCOVERY PLATFORM FOR PROTEIN MISFOLDING DISORDERS ASSOCIATED WITH METABOLITE ACCUMULATION | Non-Final OA | Ramot at Tel-Aviv University Ltd. |
| 17289620 | RASOPATHY TREATMENT | Final Rejection | The Johns Hopkins University |
| 17815849 | METHOD OF TREATING HER2-POSITIVE BREAST CANCER | Non-Final OA | University of Cincinnati |
| 17786147 | COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17786865 | CATALYTIC NUCLEIC ACID-BASED GENETIC ENGINEERING METHOD | Non-Final OA | The Board of Trustees of the University of Illinois |
| 17802004 | G PROTEIN-COUPLED RECEPTOR 146 (GPR146) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 17430991 | PRR-Activating and MicroRNA-Inhibiting Molecules and Methods of Using Same | Final Rejection | Duke University |
| 17288573 | GENE THERAPY UTILIZING VECTORS EXPRESSING RHODOPSIN TRANSGENES | Non-Final OA | Oxford University Innovation Limited |
| 18747694 | CELLS FOR GLYCOENGINEERING AND METHODS OF USE | Non-Final OA | Rock BioMedical Inc. |
| 18708618 | COMPOSITIONS FOR AQUACULTURING | Non-Final OA | ViAqua Therapeutics Ltd. |
| 16395649 | HIGH GROWTH CAPACITY AUXOTROPHIC ESCHERICHIA COLI AND METHODS OF USE | Non-Final OA | Sutro Biopharma, Inc. |
| 17721765 | Compositions for Modulating C9ORF72 Expression | Final Rejection | Ionis Pharmaceuticals, Inc. |
| 17424672 | COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION | Final Rejection | Ionis Pharmaceuticals, Inc. |
| 17594154 | ANGPTL2 ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF | Non-Final OA | Roche Innovation Center Copenhagen A/S |
| 17428322 | COMPOSITIONS FOR SUPPRESSING TRIM28 AND USES THEREOF | Non-Final OA | Memorial Sloan Kettering Cancer Center |
| 18041609 | METHODS AND APPARATUSES FOR BIOMOLECULE DELIVERY TO PRIMARY HUMAN HEMATOPOIETIC STEM CELLS USING NANOSTRAWS | Non-Final OA | NAVAN Technologies, Inc. |
| 17785565 | ANTISENSE NUCLEIC ACID ENABLING EXON SKIPPING | Non-Final OA | NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY |
| 17917522 | ENGINEERED ONCOLYTIC ADENOVIRUS | Non-Final OA | SHENZHEN HUA YAO KANG MING BIOPHARMACEUTICAL CO., LTD. |
| 17286017 | ANTISENSE THERAPY FOR PTP1B RELATED CONDITIONS | Non-Final OA | PERRON INSTITUTE FOR NEUROLOGICAL AND TRANSLATIONAL SCIENCE LIMITED |
| 17775482 | METHOD FOR SITE-SPECIFIC CONJUGATION OF NUCLEIC ACID TO CRISPR FAMILY PROTEIN, AND CONJUGATE THEREOF AND USE THEREOF | Final Rejection | BEIJING HUIDA BIOTECHNOLOGY CO., LTD |
| 17426201 | METHOD FOR DETECTING A SPECIFIC SPLICE EVENT OF A GENE OF INTEREST | Non-Final OA | Klinikum Rechts Der Isar Der Technischen Universität München |
| 17422083 | DOUBLE STRANDED RNA AND USES THEREOF | Non-Final OA | CENTRO DE NEUROCIENCIAS E BIOLOGIA CELULAR |
| 17173494 | CAS 9 RETROVIRAL INTEGRASE AND CAS 9 RECOMBINASE SYSTEMS FOR TARGETED INCORPORATION OF A DNA SEQUENCE INTO A GENOME OF A CELL OR ORGANISM | Non-Final OA | SOHM, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy